Busico Marina, Fuentes Nora A, Gallardo Adrián, Vitali Alejandra, Quintana Jorgelina, Olmos Matias, Burns Karen E A, Esperatti Mariano
Intensive Care Unit, Clínica Olivos SMG, Olivos, Buenos Aires, Argentina.
Intensive Care Unit, Hospital Privado de Comunidad, Universidad Nacional de Mar del Plata, Mar del Plata, Buenos Aires, Argentina.
Crit Care Med. 2024 Jan 1;52(1):92-101. doi: 10.1097/CCM.0000000000006056. Epub 2023 Oct 16.
The Berlin definition of acute respiratory distress syndrome (ARDS) was constructed for patients receiving invasive mechanical ventilation (IMV) with consideration given to issues related to reliability, feasibility, and validity. Notwithstanding, patients with acute respiratory failure (ARF) may be treated with high-flow nasal oxygen (HFNO) and may not fall within the scope of the original definition. We aimed to evaluate the predictive validity of the Berlin definition in HFNO-treated patients with COVID-19-related respiratory failure who otherwise met ARDS criteria.
Multicenter, prospective cohort study.
Five ICUs of five centers in Argentina from March 2020 to September 2021.
We consecutively included HFNO-treated patients older than 18 years with confirmed COVID-19-related ARF, a Pa o2 /F io2 of less than 300 mm Hg, bilateral infiltrates on imaging, and worsening respiratory symptoms for less than 1 week.
None.
We evaluated the predictive validity of mortality at day 28 using the area under the receiver operating characteristics curve (AUC), compared the predictive validity across subgroups, and characterized relevant clinical outcomes. We screened 1,231 patients and included 696 ARDS patients [30 (4%) mild, 380 (55%) moderate, and 286 (41%) severe]. For the study cohort, the AUC for mortality at day 28 was 0.606 (95% CI, 0.561-0.651) with the AUC for subgroups being similar to that of the overall cohort. Two hundred fifty-six patients (37%) received IMV. By day 28, 142 patients (21%) had died, of whom 81 (57%) had severe ARDS. Mortality occurred primarily in patients who were transitioned to IMV.
The predictive validity of the Berlin ARDS definition was similar for HFNO-treated patients as compared with the original population of invasively ventilated patients. Our findings support the extension of the Berlin definition to HFNO-treated patients with ARDS.
急性呼吸窘迫综合征(ARDS)的柏林定义是针对接受有创机械通气(IMV)的患者制定的,同时考虑了可靠性、可行性和有效性等相关问题。尽管如此,急性呼吸衰竭(ARF)患者可能接受高流量鼻导管给氧(HFNO)治疗,可能不在原始定义范围内。我们旨在评估柏林定义对符合ARDS标准但接受HFNO治疗的COVID-19相关呼吸衰竭患者的预测效度。
多中心前瞻性队列研究。
2020年3月至2021年9月期间,阿根廷五个中心的五个重症监护病房。
我们连续纳入年龄大于18岁、确诊为COVID-19相关ARF、动脉血氧分压/吸入氧分数值(Pa o2 /F io2)小于300 mmHg、影像学显示双侧浸润且呼吸症状恶化小于1周的接受HFNO治疗的患者。
无。
我们使用受试者工作特征曲线下面积(AUC)评估第28天死亡率的预测效度,比较各亚组间的预测效度,并描述相关临床结局。我们筛查了1231例患者,纳入696例ARDS患者[30例(4%)轻度、380例(55%)中度和286例(41%)重度]。对于研究队列,第28天死亡率的AUC为0.606(95%置信区间,0.561 - 0.651),各亚组的AUC与总体队列相似。256例患者(37%)接受了IMV。到第28天,142例患者(21%)死亡,其中81例(57%)患有重度ARDS。死亡主要发生在转为IMV的患者中。
与接受有创通气的原始人群相比,柏林ARDS定义对接受HFNO治疗的患者的预测效度相似。我们的研究结果支持将柏林定义扩展至接受HFNO治疗的ARDS患者。